Biotech News
Disc Medicine Raises $225.5M, Eyes Bitopertin Commercialisation
Disc Medicine, Inc., a clinical-stage biopharmaceutical company, has announced the pricing of its upsized underwritten public offering. The offering includes 3,918,182 shares of common stock priced at $55.00 per share and pre-funded warrants for 181,818 shares priced at $54.9999 per
27 January 2025